Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Naglaa Samir Bazan, MSc, PhD
Associate Professor and
Head of Clinical Pharmacy
Critical Care Medicine Department
Cairo University Hospitals.
Authored Items
Cost-Effectiveness of de novo Simvastatin as Adjunctive Therapy in Patients Critically Ill with Sepsis
Sara Mosta Eladawy, MSc, PhD
,
Mohamed Abd Alsalam Elgendy, MD
,
Mamdouh Ahmed Zaki, MD
,
Naglaa Samir Bazan, MSc, PhD
December 2022 Vol 15, No 4
in
Original Research
,
Practice Management
Last modified: December 21, 2022